Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to optimize results in neoadjuvant chemotherapy of local
advanced primary breast cancer. Therefore patients become first 3 cycles of
Epirubicin/Docetaxel followed by 3x Carboplatin/Docetaxel.